Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LIVN 
LivaNova PLC (LIVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: LIVN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -26.74% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.12B USD | Price to earnings Ratio 33.65 | 1Y Target Price 61.4 |
Price to earnings Ratio 33.65 | 1Y Target Price 61.4 | ||
Volume (30-day avg) 840601 | Beta 1.11 | 52 Weeks Range 36.85 - 64.47 | Updated Date 04/2/2025 |
52 Weeks Range 36.85 - 64.47 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.05% | Operating Margin (TTM) 11.05% |
Management Effectiveness
Return on Assets (TTM) 4.19% | Return on Equity (TTM) 4.87% |
Valuation
Trailing PE 33.65 | Forward PE 19.61 | Enterprise Value 2369264387 | Price to Sales(TTM) 1.69 |
Enterprise Value 2369264387 | Price to Sales(TTM) 1.69 | ||
Enterprise Value to Revenue 1.89 | Enterprise Value to EBITDA 11.7 | Shares Outstanding 54351800 | Shares Floating 51111313 |
Shares Outstanding 54351800 | Shares Floating 51111313 | ||
Percent Insiders 0.33 | Percent Institutions 104.52 |
Analyst Ratings
Rating 4.18 | Target Price 69.09 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
LivaNova PLC
Company Overview
History and Background
LivaNova PLC was formed in 2015 through the merger of Sorin S.p.A. and Cyberonics, Inc. Sorin had a long history in cardiovascular devices, while Cyberonics specialized in neuromodulation. The merger aimed to create a global medical technology company with a diversified portfolio.
Core Business Areas
- Cardiovascular: Develops, manufactures, and markets devices for cardiac surgery and critical care, including oxygenators, heart-lung machines, and perfusion monitoring systems.
- Neuromodulation: Develops, manufactures, and markets implantable devices for the treatment of epilepsy and depression, primarily through vagus nerve stimulation (VNS) therapy.
Leadership and Structure
The company is led by a Chief Executive Officer and a management team responsible for various functions, including finance, operations, and research and development. It has a board of directors overseeing corporate governance.
Top Products and Market Share
Key Offerings
- LifeSPARC: Advanced heart-lung machine system. Market share data is not publicly available with a specific numerical value, however they are a major player in the perfusion system space. Competitors include Medtronic and Terumo. Revenue from this product isn't public information.
- VNS Therapy System (SenTiva): Implantable device for vagus nerve stimulation therapy used to treat epilepsy and depression. Specific market share data is not publicly available, but it is a key player in the VNS segment. Competitors include Nevro and Medtronic in adjacent Neuromodulation segments. Revenue from this product isn't public information.
Market Dynamics
Industry Overview
The medical device industry is characterized by technological innovation, stringent regulatory requirements, and increasing demand due to an aging population and growing prevalence of chronic diseases.
Positioning
LivaNova PLC is positioned as a global medical technology company with a focus on cardiovascular and neuromodulation therapies. Their competitive advantages lie in their established brands, diversified product portfolio, and global distribution network.
Total Addressable Market (TAM)
The TAM for their cardiovascular and neuromodulation segments is estimated to be in the billions of dollars. LivaNova PLC is positioned to capture a portion of this TAM through continued innovation and market expansion.
Upturn SWOT Analysis
Strengths
- Established brands
- Diversified product portfolio
- Global distribution network
- Technological expertise
Weaknesses
- Past financial performance
- Dependence on key products
- Competition in mature markets
- Exposure to regulatory risks
Opportunities
- Growth in emerging markets
- Development of new therapies
- Acquisitions of complementary businesses
- Partnerships with healthcare providers
Threats
- Intense competition
- Pricing pressures
- Regulatory changes
- Product liability claims
Competitors and Market Share
Key Competitors
- MDT
- BSX
- SYK
- EW
Competitive Landscape
LivaNova PLC faces competition from larger, more diversified medical device companies. Their competitive advantages include specialized product lines and a strong presence in niche markets. Disadvantages include smaller scale and limited resources compared to larger competitors.
Major Acquisitions
MicroPort CRM (Cardiac Rhythm Management Business)
- Year: 2018
- Acquisition Price (USD millions): 190
- Strategic Rationale: Acquisition to strengthen their presence in the cardiac rhythm management market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require analysis of revenue and earnings data over the past several years. Key indicators include revenue growth rate, earnings growth rate, and return on equity.
Future Projections: Future growth projections are based on analyst estimates, which may vary. Consider factors such as market trends, product pipeline, and competitive landscape.
Recent Initiatives: Recent strategic initiatives might include product launches, acquisitions, partnerships, or cost-cutting measures. These initiatives should be evaluated for their potential impact on future growth.
Summary
LivaNova PLC is a global medical technology company with strengths in cardiovascular and neuromodulation. The company faces challenges related to competition and regulatory requirements. To enhance its growth trajectory, LivaNova PLC should focus on innovation, market expansion, and strategic acquisitions. Past financial performance and overall size needs improvements and it must be careful of larger competitors pushing them out of the market.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
EW
Edwards Lifesciences Corp
EW
Edwards Lifesciences Corp
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- LivaNova PLC Investor Relations
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on available information. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LivaNova PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1993-02-10 | CEO & Director Mr. Vladimir A. Makatsaria | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2900 | Website https://www.livanova.com |
Full time employees 2900 | Website https://www.livanova.com | ||
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.